Achaogen (AKAO) was Downgraded to a Hold Rating at SunTrust Robinson


In a report released today, Edward Nash from SunTrust Robinson downgraded Achaogen (AKAO) to Hold, with a price target of $3. The company’s shares closed yesterday at $2, close to its 52-week low of $1.75.

According to TipRanks.com, Nash is a 4-star analyst with an average return of 7.0% and a 38.8% success rate. Nash covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Adverum Biotechnologies, and CymaBay Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Achaogen with a $3 average price target, implying a 50.0% upside from current levels. In a report issued on November 9, Mizuho Securities also downgraded the stock to Hold with a $3 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15 and a one-year low of $1.75. Currently, Achaogen has an average volume of 800.8K.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts